Strengthening its Regulatory Strategy Support, Illumina Buys Myraqa | GenomeWeb

NEW YORK (GenomeWeb) – Illumina today announced it has acquired regulatory and quality consulting firm Myraqa for an undisclosed amount.

Based in Redwood Shores, Calif., Myraqa was founded in 1998 and specializes in in vitro diagnostics, particularly companion diagnostics, and focuses on regulatory strategy and application support, including premarket approvals, pre-submissions, investigational device exemptions, 510(k)s, de novo 510(k)s, and European Union technical files, Illumina said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions. 

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies. 

Mar
17
Sponsored by
Qiagen

This webinar will discuss Qiagen's approach to address two challenges facing NGS in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.